Prostate Cancer, Endometriosis, Menorrhagia and anemia cause by uterine fibroids who intends to carry out surgical resection.

Leuprolide is an agonist of luteinizing hormone-releasing hormone (LHRH); acting as a potent inhibitor of gonadotropin secretion; continuous administration results in suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. In males, testosterone levels are reduced to below castrate levels.

Following IM administration of the long-acting injectable suspension or subcutaneous administration of the long-acting injectable suspension, the drug is released slowly and gradually from its biodegradable copolymer-containing vehicle (after an initial, rapid absorption of immediately available drug), thus providing a prolonged duration of action.

Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH- RH or LH-RH derivatives; Pregnant women or women having possibilities of being pregnant, or nursing mothers; Patients with abnormal genital bleeding of indeterminable nature.

X

Because the effects of leuprolide on lactation and nursing infants currently are not known, the drug should not be used in nursing women.

feeling of hot flushes, shoulder stiffness, headache, insomnia, dizziness or diaphoresis, Injection site burning/stinging.

for adults, 11.25 mg of Leuprorelin Acetate is subcutaneously administered once every 12weeks.